{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:50:45Z","timestamp":1781704245455,"version":"3.54.5"},"reference-count":21,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Extramedullary disease (EMD) at diagnosis confers a poor prognosis in newly diagnosed multiple myeloma (NDMM). This multicenter, open-label, single-arm, phase 2, investigator-initiated trial evaluated selinexor combined with bortezomib, lenalidomide, and dexamethasone (SVRD) in NDMM with EMD. Between 17 October 2022 and 27 November 2025, 30 patients were enrolled; 29 treated patients formed the modified intention-to-treat (mITT) and safety populations (median age, 60 years). Induction comprised four 28-day SVRD cycles with protocol-specified consolidation\/maintenance and optional autologous stem cell transplantation (ASCT). The primary end point was best overall response rate (ORR) during induction according to International Myeloma Working Group criteria. Patients without a postbaseline assessment were imputed as nonresponders. In the mITT cohort, the ORR was 89.7% (stringent complete response [CR], 58.6%; CR, 3.4%; very good partial response, 10.3%; partial response, 17.2%). Imaging documented EMD regression in 89.7% of patients (complete resolution, 79.3%; partial resolution, 10.3%). The 12-month progression-free survival and overall survival rates were 87.9% and 96.3%, respectively (medians not reached; median follow-up, 18 months). High-risk cytogenetics were present in 31.0% of patients, and 27.6% met the ultra\u2013high-risk (double-hit) criteria. Grade \u22653 treatment-emergent adverse events occurred in 37.3% of patients, most commonly thrombocytopenia (24.1%), neutropenia (6.9%), and pneumonia (10.3%); no treatment-related deaths occurred. SVRD produced deep hematologic responses and high EMD clearance with manageable toxicity, thereby enabling ASCT in 51.7% of participants. These findings support SVRD as a rational frontline option for EMD-positive NDMM and justify randomized studies to confirm durability and to benchmark it against contemporary quadruplets and cellular therapies. This trial was registered at www.ClinicalTrials.gov as NCT05900882.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018945","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:51:56Z","timestamp":1769032316000},"page":"2016-2022","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-7738","authenticated-orcid":false,"given":"Yuanyuan","family":"Jin","sequence":"first","affiliation":[{"name":"1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Shi","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-4987","authenticated-orcid":false,"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-1194","authenticated-orcid":false,"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"28","key":"2026032014072796200_bib1","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blade","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026032014072796200_bib2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary multiple myeloma","volume":"54","author":"Weinstock","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2026032014072796200_bib3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2014.12.013","article-title":"Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases","volume":"15","author":"Deng","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2026032014072796200_bib4","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2026032014072796200_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026032014072796200_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2026032014072796200_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"2026032014072796200_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"issue":"10262","key":"2026032014072796200_bib9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"2026032014072796200_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcancer.2014.03.001","article-title":"Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents","volume":"27","author":"Turner","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"24","key":"2026032014072796200_bib11","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2026032014072796200_bib12","first-page":"141","article-title":"Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026032014072796200_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","article-title":"EANM guidelines on the use of [18F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders","volume":"52","author":"Nanni","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2026032014072796200_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026032014072796200_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2026032014072796200_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","article-title":"Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution","volume":"12","author":"Jimenez-Segura","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026032014072796200_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blade","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026032014072796200_bib18","first-page":"3053","article-title":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era","volume":"110","author":"Broughton","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"2026032014072796200_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"2026032014072796200_bib20","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","article-title":"Daratumumab (DARA) + bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial","volume":"42","author":"Rodr\u00edguez-Otero","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026032014072796200_bib21","doi-asserted-by":"crossref","first-page":"28557","DOI":"10.1038\/s41598-024-79537-2","article-title":"Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease","volume":"14","author":"Yin","year":"2024","journal-title":"Sci Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2016\/2509014\/blooda_adv-2025-018945-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2016\/2509014\/blooda_adv-2025-018945-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:07:37Z","timestamp":1774030057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/2016\/566167\/Efficacy-and-safety-of-selinexor-combined-with-VRD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018945","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,13]]}}}